BioRealm
Curated by SignalProvider of genotyping and software solution for the genetic study of nicotine addiction and smoking behavior
Overview
Bio Realm develops genomics and data science solutions. Its genotyping array platform called Smokescreen for research on addiction, smoking, and treatment approaches. It will be a targeted genotyping and software solution for scientists studying the genetics of nicotine addiction and smoking behavior, including those conducting clinical trials of smoking cessation therapies. It also offers services for clinical trials using Biological Markers (Biomarkers). The company has been selected by NVIDIA to be part of their Inception Program. It claims to use Affymetrix’ Axiom's genotyping technology to screen over 600k+ genetic variants to support research related to nicotine addiction, smoking cessation therapies, and consequences of tobacco use.
Key facts
- Founded
- 2006
- Headquarters
- Monument, United States
- Stage
- Sign up to view
- Industry
- Life Sciences Technology
Business model
- 6 products and services
- Sign up to view
- Commercial model
- Sign up to view
Contact
- Phone
- Sign up to view